Mikhail Blagosklonny

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mikhail Blagosklonny
Alma mater First Pavlov State Medical University of St. Peterburg
Scientific career
Fields Anti-aging medicine, oncology
Institutions

Mikhail Blagosklonny is a scientist who studies cancer and aging. He is a professor of oncology at the Roswell Park Cancer Institute in Buffalo, New York.[1]

Career[edit]

Blagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.[citation needed] He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009 when he was appointed professor of oncology at Roswell Park Cancer Institute.[1]

Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[2]

Rapamycin and aging[edit]

Blagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[3] He advocates for rapamycin use in longevity research.[4]

Editorial activities[edit]

Blagosklonny is editor-in-chief of Aging,[5] Cell Cycle,[6] and Oncotarget.[7] In addition, he is associate editor of Cancer Biology & Therapy[8] and a member of the editorial board of Cell Death & Differentiation.[9]

The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[10] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[11] in July 2015.[10] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[12]

References[edit]

  1. ^ a b "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute", Cancer Biology & Therapy, 8 (9): 753–752, May 2009, doi:10.4161/cbt.8.9.8899 
  2. ^ "Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute". Cancer Biology & Therapy. 8 (9): 753–752. May 2009. doi:10.4161/cbt.8.9.8899. 
  3. ^ Stipp, David (2011). "A New Path to Longevity". Scientific American. 306: 32–39. doi:10.1038/scientificamerican0112-32. Retrieved 2016-11-20. 
  4. ^ "Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015". Retrieved November 20, 2016. 
  5. ^ "Editorial Board". Aging. Retrieved 2016-11-20. 
  6. ^ "Editorial Board". Cell Cycle. Taylor & Francis. Retrieved 2016-11-20. 
  7. ^ "Editorial Board". Oncotarget. Retrieved 2016-11-20. 
  8. ^ "Editorial board". Cancer Biology & Therapy. Taylor & Francis. Retrieved 2016-11-20. 
  9. ^ "About the journal". Cell Death & Differentiation. Retrieved 2016-11-20. 
  10. ^ a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. Archived from the original on 20 April 2016. Retrieved 2016-11-20. 
  11. ^ Beall, Jeffrey (2016-11-20). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. Archived from the original on 2 December 2016. Retrieved 19 April 2016. 
  12. ^ "Mikhail Blagosklonny's Journal Aging: A Review". Scholarly Open Access. 6 December 2016. Archived from the original on 24 December 2016. Retrieved 17 January 2017.